VIDEO
HIGHLIGHT
Log InSign up
Trump's Rescheduling Push Meets a New Bill | TDR Cannabis in 5
SummaryTranscriptChat

Trump's Rescheduling Push Meets a New Bill | TDR Cannabis in 5

Overview of Cannabis Legislation Developments

Introduction to the Topic

  • Host Shad Dales introduces the discussion on cannabis and plant-based medicine, highlighting its relevance in light of President Trump's administration and federal marijuana rescheduling.
Summarize any video like this — free →

New Legislative Proposal

  • Republican representatives Lauren Boebert and Derek Van Orden have introduced the Advancing Botanical Drug Development Act of 2026, aimed at encouraging investment in botanical medicines including cannabis and psychedelics.

Market Exclusivity for Botanical Drugs

  • The proposed legislation would grant a 12-year market exclusivity period for FDA-approved botanical drugs, preventing approval of certain generic or hybrid applications during this time.

Financial Implications

  • Developing FDA-approved drugs is costly; supporters argue that this exclusivity will incentivize pharmaceutical companies to invest in developing botanical medicines due to potential financial returns.

Industry Insights from Experts

  • Joel Stanley, CEO of AJNA Biosciences, believes that increased exclusivity could attract more investment into natural medicines, similar to incentives seen in biological drug development.

Current Federal Landscape

Rescheduling Efforts by the Trump Administration

  • The Trump administration is moving towards rescheduling cannabis to Schedule 3, with Attorney General Todd Blanch already reclassifying state licensed medical cannabis products earlier this year.

Legal Challenges and Progress

  • A federal appeals court recently rejected attempts to halt the rescheduling process initiated by the Trump administration while litigation continues regarding cannabis classification.

DEA's Position on Cannabis Classification

  • The DEA argues that marijuana no longer meets Schedule I criteria due to its medical use acceptance, suggesting it aligns better with Schedule III regulations.

Broader Implications for Cannabis Policy

Shift Towards Recognizing Medical Use

  • There is a growing acknowledgment from federal regulators about accepted medical uses for cannabis as legislative efforts aim to create stronger incentives for developing plant-derived medicines through FDA processes.

Potential Changes in Consumer Perception

  • This movement does not equate to legalization but indicates a shift towards a federally recognized medical and pharmaceutical cannabis industry as consumer awareness increases.

Future Considerations

Legislative Process Status

  • The bill has been referred to the House Energy and Commerce Committee since August 27th; however, no hearings are scheduled yet. It’s unlikely that it will be proposed before midterms.

Companion Legislation Efforts

  • There are ongoing efforts to introduce companion legislation in the Senate alongside current developments surrounding cannabis policy at the federal level.

Conclusion and Call for Engagement

Ongoing Discussion on Cannabis Policy

  • The host encourages viewers to engage with comments regarding these developments as they signal significant changes ahead for plant medicine in America.

Anticipation of Future Announcements

  • Shad Dales concludes by expressing hope for upcoming announcements related to rescheduling efforts and emphasizes that change is on the horizon within U.S. cannabis policy.

Turn any video into a summary like this

YouTube links, meetings, lectures — with transcripts, search, and chat.

Start for free
Video description

Another interesting development is coming out of Washington involving cannabis and plant-based medicine, and once again, the timing surrounding President Trump and federal marijuana rescheduling is difficult to ignore. In this episode of TDR Cannabis in 5, host Shadd Dales breaks down reporting from Marijuana Moment on the Advancing Botanical Drug Development Act of 2026, introduced by Republican Representatives Lauren Boebert and Derrick Van Orden, which would give newly approved botanical drugs 12 years of market exclusivity, potentially unlocking real investment into cannabis and psychedelic-derived medicine. Joel Stanley, former CEO and co-founder of Charlotte's Web and now CEO of AJNA Biosciences, is developing both a cannabinoid-based treatment and a full-spectrum psilocybin compound entering Phase I trials, and told Psychedelic State(s) of America this kind of exclusivity could bring the same wave of investment to natural medicine that biologics saw years ago. There's a direct connection drawn to what's simultaneously unfolding under the Trump administration, Attorney General Todd Blanche's move placing medical cannabis into Schedule III earlier this year, a federal appeals court rejecting an attempt to block rescheduling just last week, and DEA's own argument that marijuana no longer meets Schedule I criteria. Worth noting, there's no evidence tying this bill directly to another Trump cannabis announcement, but the pattern is hard to ignore, an administration actively moving cannabis toward Schedule III, federal regulators increasingly acknowledging accepted medical use, and now Republican lawmakers building financial incentives for FDA-approved plant medicine, all happening at once. The bill still faces real hurdles, no hearing scheduled yet since its August 27 introduction, but the bigger question the episode raises is whether Washington is quietly assembling the framework for a much larger federally recognized cannabis and psychedelic medicine industry. 00:00:00 — Washington’s Plant Medicine Push 00:00:42 — New Botanical Drug Bill 00:01:19 — 12-Year Investment Incentive 00:01:53 — Cannabis Could Benefit 00:02:30 — Trump Rescheduling Connection 00:03:14 — Federal Cannabis Shift Emerging 00:04:22 — New Medical Cannabis Ecosystem 00:04:53 — Psychedelic Medicines Enter Picture 00:05:13 — What Happens Next? 00:05:48 — Cannabis as Medicine? #TDRCannabisIn5 #TrumpCannabis #CannabisRescheduling #BotanicalDrugAct #LaurenBoebert #ScheduleIII #Psychedelics #CannabisPolicy #CannabisNews #FederalCannabisPolicy Want to see more Cannabis Reform? 🎬 https://youtu.be/sPDm1EjXY-k 🎬 https://youtu.be/GfGm_OwCaAg 🎬 https://youtu.be/lp424qliyco 🎬 https://youtu.be/DilxPiAIp7c Want to stay updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked newsletter: https://newsletter.thedalesreport.com/subscribe Find us on social media and podcast platforms: ✅ Facebook: https://www.facebook.com/TheDalesReport ✅ Twitter: https://twitter.com/TheDalesReport ✅ Instagram: https://www.instagram.com/dalesreport ✅ LinkedIn: https://www.linkedin.com/company/the-dales-report/ Apple Podcasts: https://tinyurl.com/TDRTradetoBlackonApplePodcasts Spotify: https://tinyurl.com/TDRTradeToBlackonSpotify Website: https://thedalesreport.com/ For copyright matters, contact: sdales@thedalesreport.com Podcast Disclaimer (Financial Interests) The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice. The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions. By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed. Full Disclosures: https://thedalesreport.com/website-terms-of-use/